IRIDEX Corporation has appointed Maria Sainz and David Bruce to the company’s Board of Directors. Sainz and Bruce will both join the Compensation Committee. Sainz will also join the Nominating and Governance Committee. Concurrent with these additions, George Marcellino will depart from the Board of Directors to focus on his new role as IRIDEX’s vice president of Clinical Affairs.
 
“We are delighted to have two industry leaders, both with deep experience leading growth stage medical device companies, join our Board of Directors,” said William M. Moore, president and CEO.  “Their relevant experience and expertise in product development and commercialization directly aligns with our priority to accelerate Cyclo G6 adoption and utilization worldwide. Maria and David are ideal additions to our team and we look forward to their contributions.”
 
Sainz brings 25 years of experience in the medical device industry to the IRIDEX board. Sainz most recently served as president and CEO of CardioKinetix, a privately held transcatheter cardiovascular implant company. There she led the company’s regulatory, clinical and commercialization efforts outside the United States while securing expedited access pathway status for the device in America.  Previously she served as president and CEO for Concentric Medical where she contributed to ramping revenues to $36 million and negotiated the acquisition of the company by Stryker Corporation.  Prior, Sainz held several leadership positions with Guidant Corporation. She was president of the Cardiac Surgery Division for Guidant at the time of the company’s acquisition by Boston Scientific Corp., at which point she continued as an advisor to Boston Scientific. Sainz began her career at Eli Lilly & Co. She has a master of arts degree in languages from the University of Complutense in Madrid and a master's degree in international management from the American Graduate School of International Management. She currently serves on the Board of Directors for Halyard Health, Orthofix International, and MRI Interventions.
 
Bruce most recently served as chief operating officer for Catheter Robotics, a privately held, commercial stage, remote catheter systems company.  There he was responsible for planning and executing strategy for commercial market penetration, clinical studies and additional regulatory clearances for label expansion. Prior to that, Bruce served as president, CEO, and director of Arstasis, an arterial access device company, which he transitioned from development to commercialization and growth. Before Arstasis, Bruce served as CEO and director of Patient Safety Technologies, CEO and director of EP MedSystems, and platform general manager of the AcuNav Catheter Business for Siemens Medical Solutions Ultrasound Division. Bruce began his career in engineering roles at Applied Materials and Optical Storage International. He has a master's degree in business administration from the Wharton School at the University of Pennsylvania and a bachelor of science degree from the University of California, Berkeley.
 
IRIDEX Corporation develops, manufactures, and markets versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.